Lai Wang Biography and Net Worth

Global Head of R&D of Beigene

Dr. Wang joined in BeiGene’s early days, in 2011. Currently the Global Head of R&D, his previous roles in the company have included heading the Discovery Biomarkers, In Vivo Pharmacology groups and Clinical Biomarkers, and Translational Research. He was appointed as head of China Development in 2016, responsible for clinical development in the Asia-Pacific region. In 2019, he took on more responsibilities including global research, global clinical operation, and global biometrics.

Prior to joining BeiGene, Dr. Wang was the director of research at Joyant Pharmaceuticals, a biotech company based in Dallas, Texas.

Dr. Wang received his B.S. in 1996 from Fudan University and Ph.D. in 2001 from the University of Texas Health Science Center at San Antonio. He completed his post-doc training with Dr. Xiaodong Wang at Howard Hughes Medical Institute.

What is Lai Wang's net worth?: The estimated net worth of Lai Wang is at least $254.66 million as of February 21st, 2025. Dr. Wang owns 920,920 shares of Beigene stock worth more than $254,662,008 as of June 13th. This net worth estimate does not reflect any other assets that Dr. Wang may own. Learn More about Lai Wang's net worth.
How do I contact Lai Wang?: The corporate mailing address for Dr. Wang and other Beigene executives is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108. Beigene can also be reached via phone at 13459494123 and via email at [email protected]. Learn More on Lai Wang's contact information.
Has Lai Wang been buying or selling shares of Beigene?: During the past quarter, Lai Wang has sold $353,850.78 in shares of Beigene stock. Most recently, Lai Wang sold 1,402 shares of the business's stock in a transaction on Friday, June 6th. The shares were sold at an average price of $252.39, for a transaction totalling $353,850.78. Learn More on Lai Wang's trading history.
Who are Beigene's active insiders?: Beigene's insider roster includes Chan Lee (SVP), John Oyler (CEO), Lai Wang (Global Head of R&D), Lai Wang (Insider), Xiaodong Wang (Insider), and Xiaobin Wu (COO). Learn More on Beigene's active insiders.
Are insiders buying or selling shares of Beigene?: In the last twelve months, insiders at the sold shares 19 times. They sold a total of 1,238,865 shares worth more than $317,860,315.41. The most recent insider tranaction occured on June, 11th when insider Titus B. Ball sold 134 shares worth more than $34,620.24. Insiders at Beigene own 6.6% of the company. Learn More about insider trades at Beigene.
Information on this page was last updated on 6/11/2025.

Lai Wang Insider Trading History at Beigene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/6/2025	Sell	1,402	$252.39	$353,850.78
2/21/2025	Sell	5,000	$257.23	$1,286,150.00	920,920

Lai Wang Buying and Selling Activity at Beigene

Beigene Company Overview

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Today's Range

Now: $271.18

$268.69

$272.82

50 Day Range

MA: $240.18

$206.32

$276.53

2 Week Range

Now: $271.18

$141.31

$287.88

Volume

202,437 shs

Average Volume

449,297 shs

Market Capitalization

$32.10 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3